# A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

> **NCT05773820** · PHASE1,PHASE2 · RECRUITING · sponsor: **Wigen Biomedicine Technology (Shanghai) Co., Ltd.** · enrollment: 210 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** WJB001

## Key facts

- **NCT ID:** NCT05773820
- **Lead sponsor:** Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-05
- **Primary completion:** 2026-08-08
- **Final completion:** 2027-05-23
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05773820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05773820, "A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05773820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*